The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I suggested some time ago to sell up here and put the cash into a UK stock that is doing great - W7L Warpaint.
Don't take my word for it, read their year end results of 2023 published today.
Shore Capital has the following write up.
Shore Capital Today...
"...Warpaint remains highly immature across its markets, whilst at this stage in its development it does not yet have a presence in many significant markets which could represent a medium-term online opportunity (notably Southeast Asia, Japan, and South Korea). The whitespace opportunities in existing markets remain considerable, with many existing retail customers still underpenetrated (see Figure 3) and new ones to be won.
We have written for several years about how Warpaint is in the foothills for growth, such foothills have a considerable distance to traverse, and we believe strong multi-year growth beckons. In this respect, we congratulate the Warpaint team on the curation of the Group’s assortment and expedition of an exceptionally potent growth strategy.
Warpaint's market capitalisation now exceeds £350m, and so is a great success story of British enterprise and the London Stock Exchange. Seeing through the potential set out above should mean that the stock market valuation of Warpaint climbs materially further, in our view"
A long article, this is just a portion. No mention of OBD or PSE, plenty on PSA
It seems no-one knows about PSE that should do - IF OBD is at all relevant in the real world.
Dr Matthew Hobbs, Director of Research at Prostate Cancer UK, said: “A previous trial showed that screening with PSA blood tests does reduce deaths from prostate cancer but that it also misses important cancers and harms men who are given treatments or biopsies they don’t need.
“The results from the UK CaP trial are extremely significant, because they back up these findings.
“The number of men screened who still died of prostate cancer in both trials makes crystal clear that the imperative now is to develop, test, and prove new ways to diagnose prostate cancer that detect those aggressive cancers missed by PSA tests and reduce potential harm even further.”
In a separate study, researchers found that cutting the length of MRI scans for prostate cancer by a third would make them cheaper and more accessible without hindering accuracy.
Clinicians offer patients suspected of having prostate cancer an MRI scan, which is carried out in three stages.
The final step involves the patient being injected with contrast dye, which helps to enhance the images from the scan.
Removing this stage would lower costs and ensure MRIs are offered to more men, researchers from University College London (UCL) and University College London Hospitals NHS Foundation Trust said.
But they warned it is “vital” that the scans “are of optimal diagnostic quality” if this approach is to be taken.
I wrote to W7L and asked for a trading update date and results date, they replied same day and said results date would be notified soon and results date would be roughly the same as last years, so late-ish April, didn't mention a TU however (but not to say there won't be one).
I think the SP needs a bit of news now and the lack of it shows...
I imagine that the drop is probably a bit of profit taking only on lacklustre day when most stocks are down. The SP has gone up a fair bit in the last few days on no particular bit of news but as they get very good press justifiably from the likes of Walletinvestor, Stockopedia, simply wall st etc. people buy as it's just plainly a good investment. I haven't seen any bad reports on any aspect of W7L as it would seem to have none. Google W7L share price forecast and read what is said, that's what I go by...GLA
If those at the top don't care about shareholders and value of the Co. and see the SP crash about 70% weeks after launching their product - what hope is there? and the PSE test at £750 is laughable, does the average Joe know that it's supposed to be 94% accurate - I don't think so (and is it, we only have their word) and it's a lot of money for most, when there are other competitors.
I've taken the hit and got out of this rubbish.
Kongolasse writes that 67% is titanite, leaving 33% of what? Not Titanium I guess...
Going by the share price today looks like the dream is over already
I'll be interested to know what value is left, is it worth more testing etc.
All comments welcome
Spending on big ticket items down, and instant gratification (Greggs sausage rolls!) and make up is strong, I imagine it's the same the world over at present, we need an affordable treat to counter the gloom and doom. I think the Finals on 30th April will be even better than the last set of results (which were stunning) and the SP will re-rate yet again so I'm buying the small dips in SP. The people buying W7L products are mainly quite young and very 'body conscious' thanks to social media and societal change - anything goes it seems to me! All absolutely in W7L's favour - they are in the right time with the right products around the world and expanding fast imho. GLA
Not knowing anything about mining but appreciating the scale of the 'find' and accepting that the lab results take time, when do you think there could be verified calculations of possible scenarios that would be clear to the markets to make this fly (if it's as good as was expressed by Shaun Bunn) either by a takeover or joint venture.
I'd think it all depends on the lab results. Maybe 6 months or sooner? Any info in layman's terms appreciated. GLA
They are going to be bought out some way very soon, maybe by some outfit that would sell PSE at a reasonable cost nothing like £750, and have a clue about marketing and business which the present lot don't.
I guess the science is good but it's just a guess as I don't know now what to believe.
In responce to Taverham's post
'The best defence Burrows can offer is to say USA is 5 times the UK market so that is our priority'
Does anyone know how the US is doing?
Any answers much appreciated
Does anyone have any info re: the US.
I'm afraid that I haven't the time to find information and have found it hard when I have had time in the past few months.
I'd think that big pharma over there would be quicker to make a bid for the Co. or relevant IP etc. than in the UK simply being a far larger market and given US Govt. support. In fact it doesn't bode well if there is not some interest shown right now.
I'm hanging on with my holding purely now in the hope of a takeover. If there is no no statement as to what OBD's future intentions I guess I'll take the loss and plough it into Warpaint (W7L) that has done extraordinarily well in the past year.
GLA
No mention of PSE at all.
What a great missed opportunity OBD have made through hopeless management. One of the biggest ever perhaps, certainly in the medical field.
I hope a takeover comes very quickly
I hope for a buyout in some form by big pharma to monetize the science and for OBD to concentrate on the science. Leave marketing and shareholder dealings to business pro's. The sooner the better. This set of results damages the science aspects, never good to be a laughing stock or to embitter investors.
All the news is so good and with the new markets the brand will attract more shoppers globally enhancing the ability for more products and increased awareness of shoppers and investors imho
As it would seem most of central and south America is going or is now narco with drugs and guns and cartels being the prime movers in countries with failing economies I wonder if Argentina is at risk of Cartels taking over. The economy being shot for years and the Milei bitter medicine making it a lot worse for the average Joe. Maybe it's not reported?